Jack Allen
Stock Analyst at Robert W. Baird
(0.04)
# 4,730
Out of 4,996 analysts
334
Total ratings
28.8%
Success rate
-16.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jack Allen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CLLS Cellectis | Reiterated: Buy | $10 → $8 | $1.44 | +455.56% | 27 | Sep 15, 2026 | |
| RARE Ultragenyx Pharmaceutical | Downgraded: Hold | $40 → $16 | $14.88 | +7.53% | 13 | Sep 3, 2026 | |
| TSHA Taysha Gene Therapies | Reiterated: Buy | $12 → $15 | $4.91 | +205.50% | 27 | Jun 30, 2026 | |
| FTH Faeth Therapeutics | Initiated Coverage: Buy | $57 | $31.55 | +80.67% | 1 | Jun 26, 2026 | |
| LYEL Lyell Immunopharma | Initiated Coverage: Buy | $49 | $10.56 | +364.02% | 1 | May 1, 2026 | |
| NTLA Intellia Therapeutics | Reiterated: Hold | $7 → $13 | $12.33 | +5.43% | 25 | Apr 27, 2026 | |
| ALLO Allogene Therapeutics | Reiterated: Buy | $7 → $9 | $1.67 | +438.92% | 23 | Apr 14, 2026 | |
| TIL Instil Bio | Downgraded: Hold | $180 → $7 | $7.24 | -3.25% | 28 | Jan 7, 2026 | |
| MREO Mereo BioPharma Group | Reiterated: Buy | $8 → $1 | $0.3403 | +193.86% | 5 | Dec 29, 2025 | |
| VOR Vor Biopharma | Reiterated: Buy | $64 → $46 | $19.37 | +137.48% | 29 | Dec 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $52 → $44 | $55.76 | -21.09% | 13 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5 | $0.9567 | n/a | 20 | Sep 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 → $6 | $2.69 | n/a | 9 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $18 | $2.87 | n/a | 27 | Jul 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $5 → $4 | $2.43 | n/a | 11 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.0007 | n/a | 14 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $12.35 | n/a | 17 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $84 | $31.54 | n/a | 9 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $72 → $65 | $62.21 | n/a | 9 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $27 | $9.56 | n/a | 17 | Nov 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $200 → $25 | $9.83 | n/a | 9 | Sep 26, 2023 |
Cellectis
Sep 15, 2026
Reiterated: Buy
Price Target: $10 → $8
Current: $1.44
Upside: +455.56%
Ultragenyx Pharmaceutical
Sep 3, 2026
Downgraded: Hold
Price Target: $40 → $16
Current: $14.88
Upside: +7.53%
Taysha Gene Therapies
Jun 30, 2026
Reiterated: Buy
Price Target: $12 → $15
Current: $4.91
Upside: +205.50%
Faeth Therapeutics
Jun 26, 2026
Initiated Coverage: Buy
Price Target: $57
Current: $31.55
Upside: +80.67%
Lyell Immunopharma
May 1, 2026
Initiated Coverage: Buy
Price Target: $49
Current: $10.56
Upside: +364.02%
Intellia Therapeutics
Apr 27, 2026
Reiterated: Hold
Price Target: $7 → $13
Current: $12.33
Upside: +5.43%
Allogene Therapeutics
Apr 14, 2026
Reiterated: Buy
Price Target: $7 → $9
Current: $1.67
Upside: +438.92%
Instil Bio
Jan 7, 2026
Downgraded: Hold
Price Target: $180 → $7
Current: $7.24
Upside: -3.25%
Mereo BioPharma Group
Dec 29, 2025
Reiterated: Buy
Price Target: $8 → $1
Current: $0.3403
Upside: +193.86%
Vor Biopharma
Dec 23, 2025
Reiterated: Buy
Price Target: $64 → $46
Current: $19.37
Upside: +137.48%
Nov 11, 2025
Reiterated: Hold
Price Target: $52 → $44
Current: $55.76
Upside: -21.09%
Sep 23, 2025
Reiterated: Buy
Price Target: $5
Current: $0.9567
Upside: n/a
Aug 13, 2025
Reiterated: Buy
Price Target: $10 → $6
Current: $2.69
Upside: n/a
Jul 17, 2025
Reiterated: Buy
Price Target: $18
Current: $2.87
Upside: n/a
May 14, 2025
Reiterated: Hold
Price Target: $5 → $4
Current: $2.43
Upside: n/a
May 12, 2025
Rated: Hold
Price Target: n/a
Current: $0.0007
Upside: n/a
May 12, 2025
Rated: Hold
Price Target: n/a
Current: $12.35
Upside: n/a
Nov 6, 2024
Reiterated: Buy
Price Target: $84
Current: $31.54
Upside: n/a
Oct 30, 2024
Reiterated: Hold
Price Target: $72 → $65
Current: $62.21
Upside: n/a
Nov 16, 2023
Reiterated: Hold
Price Target: $27
Current: $9.56
Upside: n/a
Sep 26, 2023
Downgraded: Hold
Price Target: $200 → $25
Current: $9.83
Upside: n/a